OTC: IPSEF - Ipsen S.A.

Rentabilité sur six mois: +2.5%
Rendement en dividendes: +0.96%
Secteur: Healthcare

Calendrier des promotions Ipsen S.A.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma.

plus de détails
The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета eur
Див.доход ао 0.9639
Дивиденд ао 1.16
Сайт https://www.ipsen.com
Цена ао 120.55
Changement de prix par jour: 0% (120.55)
Changement de prix par semaine: 0% (120.55)
Changement de prix par mois: 0% (120.55)
Changement de prix sur 3 mois: -3.84% (125.37)
Changement de prix sur six mois: +2.5% (117.61)
Changement de prix par an: +2.51% (117.6)
Evolution des prix depuis le début de l'année: -3.84% (125.37)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 2.63 6
P/BV 2.15 7
P/E 12.77 8
EV/EBITDA 8.63 8
Total: 7.88

Efficacité

Nom Signification Grade
ROA, % 10.19 4
ROE, % 16.85 5
Total: 5

Dividendes

Nom Signification Grade
Div yield, % 0.9639 2.4
DSI 0.8571 8.57
Total: 2.86

Devoir

Nom Signification Grade
Debt/EBITDA 0.4137 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 22.79 4
Rentabilité Ebitda, % 4.08 1
Rentabilité EPS, % -1246.72 0
Total: 2.8
Plus de détails



Superviseur Titre d'emploi Paiement Année de naissance
Mr. David Loew MD, CEO & Director 2.41M 1967 (58 années)
Mr. Aymeric Le Chatelier Executive VP & CFO 792.51k 1969 (56 années)
Dr. Aidan Murphy Ph.D. Executive VP and Head of Technical Operations N/A 1966 (59 années)
Mr. Craig Marks Vice-President of Investor Relations N/A
Mr. Francois Garnier Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer N/A 1962 (63 année)
Mr. Regis Mulot Executive VP & Chief Human Resources Officer N/A 1966 (59 années)
Ms. Dominique Bery Head of Nordics & Baltics N/A 1971 (54 année)
Mr. Bartosz Bednarz D.D.S. Executive VP and Head of Global Product & Portfolio Strategy N/A
Mr. Philippe Lopes-Fernandes CBO Executive VP & Chief Business Officer N/A
Dr. James Levine M.D., Ph.D. President of Fondation Ipsen

Adresse: France, Boulogne-Billancourt, 65 quai Georges Gorse - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.ipsen.com